Advertisement
Advertisement
U.S. markets open in 5 hours
S&P Futures
4,327.75 +10.00 (+0.23%) Dow Futures
34,055.00 +12.00 (+0.04%) Nasdaq Futures
14,088.00 +101.25 (+0.72%) Russell 2000 Futures
1,920.80 -7.50 (-0.39%) Crude Oil
86.87 +0.26 (+0.30%) Gold
1,789.50 -3.60 (-0.20%)
At close: 04:00PM EST
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 189.98 |
| Open | 189.87 |
| Bid | 183.58 x 900 |
| Ask | 190.00 x 1000 |
| Day's Range | 188.21 - 193.37 |
| 52 Week Range | 184.48 - 336.99 |
| Volume | |
| Avg. Volume | 119,432 |
| Market Cap | 2.205B |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | 14.23 |
| EPS (TTM) | 13.34 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | 5.68 (2.99%) |
| Ex-Dividend Date | Dec 20, 2021 |
| 1y Target Est | 348.00 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
97% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- MEDIFAST INCMED: Lowering target price to $202.00MEDIFAST INC has an Investment Rating of HOLD; a target price of $202.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat2 days agoArgus Research
- Zacks
Altria (MO) Q4 Earnings Match Estimates, Revenues Fall Y/Y
Altria Group's (MO) fourth-quarter 2021 results reflect an increased bottom line, while the top line declines year over year. Pricing remains an upside.
- Zacks
McCormick's (MKC) Q4 Earnings Beat Estimates, Sales Up Y/Y
McCormick's (MKC) fourth-quarter fiscal 2021 results reflect the impact of higher sales driven by growth in the Flavor Solutions and Consumer units. Also, earnings increase in the quarter.
- Zacks
Medifast (MED) Looks Great on OPTAVIA, Strategic Investments
Medifast (MED) has been benefiting from the strength of its OPTAVIA lifestyle solution and coaching support system, as well as efficient technological investments.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
